R

RELX

Global information analytics and decision tools

Digital Content Editor 1

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
Bachelor's
Manila, Metro Manila, Philippines
In Person
Content & WritingEditing & Proofreading

About the job

Requirements
  • The candidate must hold at least a college degree.
  • The candidate must have strong attention to detail and sharp analytical skills.
  • The candidate must have above-average written and oral communication skills in US English and be comfortable dealing with foreign partners and stakeholders.
  • The candidate must have solid multitasking and time-management skills and be flexible in a fast-paced, deadline-driven environment.
  • The candidate must be proficient in Adobe InDesign, Adobe Photoshop, Arbortext, basic computer skills, and MS Office applications.
  • The candidate must have copy-editing skills and familiarity with the Internet and online information searching.
  • The candidate must have passed USCA Task Based Certification for Digital Content Editor.
  • The candidate must have completed certification training in publication management, including outsourcing, content enhancement, cite checking, copy editing, cite validation, Finding Aid Table (FAT), Automated Filing Instructions (AFI), release finalizing, print clear processing, and web scraping (PG/LPA).
  • The candidate must have completed certification training in print and digital composition, including desktop publishing, intermediate Adobe InDesign formatting, XML tag and merge, VISF tagging, graphics and Adobe Photoshop, and MS Word formatting.
  • The candidate must have completed electronic conversion training in data validation, cite checking, eBook, online and Alpha conversion, and quality checking of print and electronic files, press-ready files, and index compositions.
  • The candidate must have completed newsletter certification training comparable to the work performed by Legal Publication Owners, Legal Editors, Legal Practice Advisors, the Make-Ready Team, and Coordinators of Publications Operation.
Responsibilities
  • Coordinate closely with the partnering local Legal Editor or Operations Analysts and US and Canadian stakeholders, suppliers, the Manufacturing Buyer, and Subject Matter Experts to deliver publications on time.
  • Ensure each assigned publication meets business requirements for turnaround time and quality.
  • Coordinate schedule revisions when needed and promptly notify the immediate supervisor of unresolved issues that may delay a publication's release and cause monthly revenue loss.
  • Lead calls with US counterparts and stakeholders about the publications being handled.
  • Support delivery of print and electronic publications in accordance with production-cycle-time and accuracy requirements.
  • Manage assigned publications and initiate final product-output extraction and delivery according to schedule or content-owner signoff.
  • Post weekly and monthly reports and status updates on time, and complete cleanup tasks in addition to daily milestones.
  • Follow production, tracking, and communication best practices; identify potential errors, roadblocks, and future issues; remediate problems and formulate process improvements.
  • Coordinate daily activities and production milestones with local Legal Editors or Operations Analysts, US stakeholders, Canadian operations, Legal Practice Advisors, the Manufacturing Buyer, suppliers, and Subject Matter Experts.
  • Manage Webstar by updating statuses and action items and coordinating with responsible teams or individuals to resolve issues submitted through Webstar tickets.
  • Perform administrative and organizational tasks needed to complete products and projects on time.
  • Perform rules-based quality assurance and proof review in the accelerated desktop-editing process, following established standards and verifying styling, formatting, and standardization rules.
  • Support team decisions and a supportive team environment; assist colleagues with production needs, share knowledge and expertise, mentor colleagues, and identify knowledge gaps and opportunities to build competence within the team, department, and US counterparts.

About the company

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Get referred to RELX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 revenue grew 7%; Legal grew 10%; Risk grew 8%.
  • February 24, 2026 Lexis+ with Protégé launched globally, expanding AI workflow adoption.
  • September 3, 2026 Doctrine closes, targeting one million European legal professionals.

What critics are saying

  • Anthropic and Thomson Reuters compressed legal AI pricing after February 2026 market shock.
  • Harvey and Legora court law schools in 2026, training future buyer cohorts elsewhere.
  • Exhibitions face Middle East event uncertainty through 2026, threatening margins and calendar-dependent cash flows.

What makes RELX unique

  • LexisNexis’ 200 billion-document corpus still beats generic legal AI models.
  • September 3, 2026 Doctrine acquisition deepens RELX’s European legal AI workflow moat.
  • H1 2026 subscriptions supplied 62% of revenue, stabilizing cash generation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

Citybiz
Apr 28th, 2026
RELX to Acquire Legaltech Platform Doctrine in European AI Push

RELX Group has entered into an agreement to acquire French legal technology company Doctrine, a move that would expand its... Read More

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence